Informatie:
Fout:
ID
31974
Beschrijving
Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care; ODM derived from: https://clinicaltrials.gov/show/NCT01163916
Link
https://clinicaltrials.gov/show/NCT01163916
Trefwoorden
Versies (1)
- 09-10-18 09-10-18 -
Houder van rechten
See clinicaltrials.gov
Geüploaded op
9 oktober 2018
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Rheumatoid Arthritis NCT01163916
Eligibility Rheumatoid Arthritis NCT01163916
- StudyEvent: Eligibility
Similar models
Eligibility Rheumatoid Arthritis NCT01163916
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Indication Adalimumab
Item
patients for whom adalimumab therapy is indicated according to product label and who meet the following criteria:
boolean
C3146298 (UMLS CUI [1,1])
C1122087 (UMLS CUI [1,2])
C1122087 (UMLS CUI [1,2])
Adalimumab prescribed newly | infliximab
Item
patients who are newly prescribed adalimumab therapy (no prior history of treatment with adalimumab) including patients with infliximab treatment history.
boolean
C1122087 (UMLS CUI [1,1])
C0278329 (UMLS CUI [1,2])
C0750546 (UMLS CUI [1,3])
C0666743 (UMLS CUI [2])
C0278329 (UMLS CUI [1,2])
C0750546 (UMLS CUI [1,3])
C0666743 (UMLS CUI [2])
Clinical Trials Specified Completed | adalimumab
Item
patients who completed abbott sponsored interventional trials and are continuing treatment with commercial adalimumab thereafter.
boolean
C0008976 (UMLS CUI [1,1])
C0205369 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
C1122087 (UMLS CUI [2])
C0205369 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
C1122087 (UMLS CUI [2])
Patients Excluded
Item
the following patients will not be included in the study:
boolean
C0030705 (UMLS CUI [1,1])
C0332196 (UMLS CUI [1,2])
C0332196 (UMLS CUI [1,2])
Pharmaceutical Preparations At risk Interactions Adalimumab
Item
patients who are being treated or will be treated with drugs at risk of interactions with adalimumab.
boolean
C0013227 (UMLS CUI [1,1])
C1444641 (UMLS CUI [1,2])
C0687133 (UMLS CUI [1,3])
C1122087 (UMLS CUI [1,4])
C1444641 (UMLS CUI [1,2])
C0687133 (UMLS CUI [1,3])
C1122087 (UMLS CUI [1,4])
Hypersensitivity Adalimumab
Item
hypersensitivity to adalimumab
boolean
C0020517 (UMLS CUI [1,1])
C1122087 (UMLS CUI [1,2])
C1122087 (UMLS CUI [1,2])
Pregnancy
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])
Breast Feeding
Item
lactation
boolean
C0006147 (UMLS CUI [1])
Age
Item
age below 18
boolean
C0001779 (UMLS CUI [1])
Communicable Diseases | Tuberculosis
Item
infectious diseases including tuberculosis
boolean
C0009450 (UMLS CUI [1])
C0041296 (UMLS CUI [2])
C0041296 (UMLS CUI [2])
Study Subject Participation Status
Item
patients currently participating in another clinical trial.
boolean
C2348568 (UMLS CUI [1])